ArticleProceedings of the National Academy of Sciences of the United States of America2013
Single-dose vaccine against tick-borne encephalitis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2014Pooled it
- Influence of the pre-membrane and envelope proteins on structure, pathogenicity, and tropism of tick-borne encephalitis virus.Journal of virology · 2025Article
- Research progress toward arthropod salivary protein vaccine development for vector-borne infectious diseases.PLoS neglected tropical diseases · 2024Review
- Editorial: Immunological aspects of emerging and re-emerging zoonoses.Frontiers in immunology · 2024Article
- Replication-Deficient Zika Vector-Based Vaccine Provides Maternal and Fetal Protection in Mouse Model.Microbiology spectrum · 2022Article
- The role of capsid in the flaviviral life cycle and perspectives for vaccine development.Vaccine · 2020Review
- Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise.Vaccines · 2020Review
- Zika virus tropism during early infection of the testicular interstitium and its role in viral pathogenesis in the testes.PLoS pathogens · 2020Article
- Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.Scientific reports · 2019Article
- Article
- Tick-Borne Flaviviruses, with a Focus on Powassan Virus.Clinical microbiology reviews · 2019Review
- Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach.Journal of virology · 2018Article
- Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.Scientific reports · 2018Article
- Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets.Human vaccines & immunotherapeutics · 2017Article
- Article
- A Roadmap for Tick-Borne Flavivirus Research in the "Omics" Era.Frontiers in cellular and infection microbiology · 2017Review
- The Emerging Duck Flavivirus Is Not Pathogenic for Primates and Is Highly Sensitive to Mammalian Interferon Antiviral Signaling.Journal of virology · 2016Article
- MicroRNA-based control of tick-borne flavivirus neuropathogenesis: Challenges and perspectives.Antiviral research · 2016Article
- Article
- Current status and future prospects of yellow fever vaccines.Expert review of vaccines · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis (TBE) virus is the most important human pathogen transmitted by ticks in Eurasia. Inactivated vaccines are available but require multiple doses and frequent boosters to induce and maintain immunity. Thus far, the goal of developing a safe, live attenuated vaccine effective after a single dose has remained elusive. Here we used a replication-defective (single-cycle) flavivirus platform, RepliVax, to generate a safe, single-dose TBE vaccine. Several RepliVax-TBE candidates attenuated by a deletion in the capsid gene were constructed using different flavivirus backbones containing the envelope genes of TBE virus. RepliVax-TBE based on a West Nile virus backbone (RV-WN/TBE) grew more efficiently in helper cells than candidates based on Langat E5, TBE, and yellow fever 17D backbones, and was found to be highly immunogenic and efficacious in mice. Live chimeric yellow fever 17D/TBE, Dengue 2/TBE, and Langat E5/TBE candidates were also constructed but were found to be underattenuated. RV-WN/TBE was demonstrated to be highly immunogenic in Rhesus macaques after a single dose, inducing a significantly more durable humoral immune response compared with three doses of a licensed, adjuvanted human inactivated vaccine. Its immunogenicity was not significantly affected by preexisting immunity against WN. Immunized monkeys were protected from a stringent surrogate challenge. These results support the identification of a single-cycle TBE vaccine with a superior product profile to existing inactivated vaccines, which could lead to improved vaccine coverage and control of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.